No Picture
Boston Cambridge Biotech Trending News

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present novel biomarker data from […]

No Picture
Boston Cambridge Biotech Trending News

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

CAMBRIDGE, Mass. & COLUMBUS, Ohio–(BUSINESS WIRE)– #genetherapy–Solid and Forge Announce Viral Vector Contract Development and cGMP Manufacturing Partnership Click here to view original post

No Picture
Boston Cambridge Biotech Trending News

SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. […]

No Picture
Boston Cambridge Biotech Trending News

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock announces an e-poster presentation of clinical results from the TOPAZ Phase 2 trial at the 25th World Congress of Neurology (WCN). Click here to view original post

Boston Cambridge Biotech Trending News

Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three […]

No Picture
Boston Cambridge Biotech Trending News

Agenus to Present AGEN1181 Clinical Data at SITC

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and […]

No Picture
Boston Cambridge Biotech Trending News

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Oct. 1, 2021 /PRNewswire/ — Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced it will have two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) […]

No Picture
Boston Cambridge Biotech Trending News

Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $IMV #DeliveryPlatform–IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data […]